Genomic profiling for clinical decision making in lymphoid neoplasms
L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Langerhans cell histiocytosis: current advances in molecular pathogenesis
Langerhans cell histiocytosis (LCH) is a rare and clinically heterogeneous hematological
disease characterized by the accumulation of mononuclear phagocytes in various tissues …
disease characterized by the accumulation of mononuclear phagocytes in various tissues …
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
PG Kemps, TCE Zondag, HB Arnardottir… - Blood …, 2023 - ashpublications.org
Langerhans cell histiocytosis (LCH) is a rare neoplastic disorder caused by somatic genetic
alterations in hematopoietic precursor cells differentiating into CD1a+/CD207+ histiocytes …
alterations in hematopoietic precursor cells differentiating into CD1a+/CD207+ histiocytes …
Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures
K Bielamowicz, P Dimitrion, O Abla, S Bomken… - Cancer, 2024 - Wiley Online Library
Langerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder characterized by
lesions with CD1a‐positive/Langerin (CD207)‐positive histiocytes and inflammatory infiltrate …
lesions with CD1a‐positive/Langerin (CD207)‐positive histiocytes and inflammatory infiltrate …
Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis
V Karri, H Lin, J Velazquez, A Batajoo… - British Journal of …, 2024 - Wiley Online Library
Optimal therapeutic approaches for advanced Langerhans cell histiocytosis (LCH) are not
known. We assessed the safety and efficacy of combined chemotherapy with MAPK pathway …
known. We assessed the safety and efficacy of combined chemotherapy with MAPK pathway …
[HTML][HTML] Langerhans Cell Histiocytosis with Good Response to Low-Dose Imatinib: Case Report and Literature Review
M Abdulagayoom, D Mudawi, Z Lengyel… - Case Reports in …, 2023 - karger.com
Langerhans cell histiocytosis (LCH) is a rare neoplastic disease characterized by infiltration
of histiocytes and dendritic cells into body organs. While treatment is better established in …
of histiocytes and dendritic cells into body organs. While treatment is better established in …
Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
Histiocytic disorders are rare hematologic neoplasms characterized by a notable
dependence on mitogen-activated protein kinase signaling. With conventional therapies, a …
dependence on mitogen-activated protein kinase signaling. With conventional therapies, a …
Overall manifestations and survival of pediatric patients with Langerhans cell histiocytosis. A middle-income country (mic) national multicenter study.
L Velasco-Hidalgo, A González-Garay… - Boletín Médico del …, 2024 - search.ebscohost.com
Background: Langerhans cell histiocytosis (LCH) is a rare neoplastic disease characterized
by clonal proliferation of dendritic cells. It is Mexico's ninth most frequent malignancy in …
by clonal proliferation of dendritic cells. It is Mexico's ninth most frequent malignancy in …
[PDF][PDF] rnardóttir, HB, Solle eld-Westerink, N
PG Kemps, TCE Zondag - … Steenwi k, EC …, 2023 - scholarlypublications …
Langerhans cell histiocytosis (LCH) is a rare hematologic neoplasm characterized by the
accumulation of myeloiddifferentiated cells with characteristic CD1a and CD207 expression …
accumulation of myeloiddifferentiated cells with characteristic CD1a and CD207 expression …